IMPACT Therapeutics, Inc (HKG:7630)

Market Cap	11.76B
Revenue (ttm)	42.57M +14.0%
Net Income	-329.31M
EPS	-1.44
Shares Out	276.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,400
Open	40.14
Previous Close	39.90
Day's Range	39.30 - 43.08
52-Week Range	28.20 - 47.98
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMPACT Therapeutics

IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; IMP9064, an ataxia tel...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2009
• Employees: 58
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 7630

Financial Performance

Financial numbers in CNY